Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29602099 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL17746950 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL30608469 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL16915228 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL29484077 | 1.00 | KMT2A (0.61) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL17746952 | 0.93 | KMT2A (0.65) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL17746951 | 0.93 | KMT2A (0.65) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL30905448 | 0.93 | KMT2A (0.65) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL2089280 | 0.92 | KMT2A (0.67) | KMT2ASLC1A3SLC1A1EPHX2MDM4 | |
| SCHEMBL10052316 | 0.92 | KMT2A (0.67) | KMT2ASLC1A3SLC1A1EPHX2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-11952434-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230101323-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-30 | — | — | US | disclosed |
| CN-114652813-A | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11358988-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-14 | — | — | US | disclosed |
| CN-107108698-B | Macrocyclic peptides as immunomodulators | 百时美施贵宝公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3778622-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3218392-B1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200216498-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-09 | — | — | US | disclosed |
| EP-0835262-A1 | METHOD FOR THE TREATMENT OF CORTICOSTEROID INDUCED OSTEOPENIA | SYNTEX (U.S.A.) INC. (US) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997049432-A9 | TREATMENT AND PREVENTION OF CANCER BY ADMINISTRATION OF DERIVATIVES OF HUMAN CHORIONIC GONADOTROPIN | — | 1998-03-19 | — | — | WO | disclosed |
| WO-1997049721-A1 | METHODS OF TREATMENT OF WASTING SYNDROME BASED ON ADMINISTRATION OF DERIVATIVES OF HUMAN CHORIONIC GONADOTROPIN | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049432-A1 | TREATMENT AND PREVENTION OF CANCER BY ADMINISTRATION OF DERIVATIVES OF HUMAN CHORIONIC GONADOTROPIN | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049418-A1 | METHODS OF PROMOTING HEMATOPOIESIS USING DERIVATIVES OF HUMAN CHORIONIC GONADOTROPIN | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049373-A2 | TREATMENT AND PREVENTION OF HIV INFECTION BY ADMINISTRATION OF DERIVATIVES OF HUMAN CHORIONIC GONADOTROPIN | UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997007815-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL DELIVERY OF COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1997-03-06 | — | — | WO | disclosed |
| WO-1996040775-A1 | METHOD FOR THE TREATMENT OF CORTICOSTEROID INDUCED OSTEOPENIA | SYNTEX (U.S.A.) INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0651765-A1 | ANALOGS OF PTH AND PTHRP, THEIR SYNTHESIS AND USE FOR THE TREATMENT OF OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994001460-A1 | ANALOGS OF PTH AND PTHRP, THEIR SYNTHESIS AND USE FOR THE TREATMENT OF OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952434-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885SLC1A3 4533/4885SLC1A1 4448/4885 |
| US-20230101323-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885SLC1A3 4533/4885SLC1A1 4448/4885 |
| US-11358988-B2 | Immunomodulators | CD74, ICOS, HAVCR2 | KMT2A 3513/4885SLC1A3 4533/4885SLC1A1 4448/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | KMT2A 2293/4885SLC1A3 4582/4885SLC1A1 4538/4885 |
| US-20200216498-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | KMT2A 3513/4885SLC1A3 4533/4885SLC1A1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.